NASDAQ:CGTX

Cognition Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CGTX

*Your capital is at risk

$1.42

+0.0700 (+5.19%)

At Close: Jun 03, 2026

Cognition Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 81.55. In total, the insiders bought 5.21M and sold 470.38K CGTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	81.55
● Buy	5.21M shares
● Sell	470.38K shares
68% Buy Activity Weak Negative Correlation
Sell Signal Low Confidence Feb 04, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 81.55. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 01, 2026 Sell	Common Stock F-InKind	Doyle John Brendan Chief Financial Officer	C-Suite Officer	8 567 Value: $11.0K
Apr 16, 2026 Buy	Common Stock P-Purchase	Ricciardi Lisa CEO & President	CEO / President	9 175 Value: $10.1K
Apr 16, 2026 Buy	Common Stock P-Purchase	Doyle John Brendan Chief Financial Officer	C-Suite Officer	10 000 Value: $11.3K
Apr 16, 2026 Buy	Common Stock P-Purchase	Caggiano Anthony Chief Medical Officer	Officer	10 000 Value: $11.1K
Feb 15, 2026 Sell	Common Stock F-InKind	Caggiano Anthony Chief Medical Officer	Officer	4 680 Value: $5K
Feb 15, 2026 Sell	Common Stock F-InKind	Ricciardi Lisa CEO & President	CEO / President	5 850 Value: $7K
Feb 15, 2026 Sell	Common Stock F-InKind	Doyle John Brendan Chief Financial Officer	C-Suite Officer	1 560 Value: $2K
Feb 04, 2026 Sell	Common Stock F-InKind	Ricciardi Lisa CEO & President	CEO / President	51 704 Value: $53.3K
Feb 04, 2026 Sell	Common Stock F-InKind	Doyle John Brendan Chief Financial Officer	C-Suite Officer	26 921 Value: $27.7K
Feb 04, 2026 Sell	Common Stock F-InKind	Caggiano Anthony Chief Medical Officer	Officer	26 919 Value: $27.7K
Feb 03, 2026 Sell	Common Stock F-InKind	Caggiano Anthony Chief Medical Officer	Officer	11 488 Value: $12.9K
Feb 03, 2026 Buy	Common Stock A-Award	Caggiano Anthony Chief Medical Officer	Officer	400 000 Value: $448.0K
Feb 03, 2026 Sell	Common Stock F-InKind	Ricciardi Lisa CEO & President	CEO / President	26 036 Value: $29.2K
Feb 03, 2026 Buy	Common Stock A-Award	Ricciardi Lisa CEO & President	CEO / President	800 000 Value: $896.0K
Feb 03, 2026 Buy	Common Stock A-Award	Doyle John Brendan Chief Financial Officer	C-Suite Officer	200 000 Value: $224.0K
Dec 18, 2025 Buy	Common Stock A-Award	Caggiano Anthony Chief Medical Officer	Officer	65 000 Value: $97.5K
Dec 18, 2025 Sell	Common Stock F-InKind	Ricciardi Lisa CEO & President	CEO / President	23 400 Value: $35.1K
Dec 18, 2025 Buy	Common Stock A-Award	Ricciardi Lisa CEO & President	CEO / President	75 000 Value: $112.5K
Dec 18, 2025 Sell	Common Stock F-InKind	Caggiano Anthony Chief Medical Officer	Officer	20 280 Value: $30.4K
Dec 18, 2025 Buy	Common Stock A-Award	Doyle John Brendan Chief Financial Officer	C-Suite Officer	30 000 Value: $45.0K
Dec 18, 2025 Sell	Common Stock F-InKind	Doyle John Brendan Chief Financial Officer	C-Suite Officer	9 360 Value: $14.0K
Sep 19, 2025 Buy	Common Stock M-Exempt	Fletcher Aaron G.l.	Director	7 729 Value: $6K
Sep 19, 2025 Buy	Stock Option (right to buy) M-Exempt	Fletcher Aaron G.l.	Director	7 729 Value: $6K
Sep 19, 2025 Buy	Stock Option (right to buy) M-Exempt	Fletcher Aaron G.l.	Director	7 729 Value: $6K
Sep 19, 2025 Buy	Common Stock M-Exempt	Fletcher Aaron G.l.	Director	7 729 Value: $6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT COGNITION THERAPEUTICS, INC.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinica...

Read Full Profile Here